Kura Oncology, Inc.

Pfizer Corporation

Molecular Templates, Inc.

Veridex, Lcc

Kura Oncolofy, Inc.

Pfizer Products Inc.

Antonio Gualberto

Catherine Rose Scholz

Carrie L Melvin

Mark Carle Connelly

Bruce D Cohen

Charles Praray Hart

Brian A Elenbaas

Madeline I Repollet

David Chianese

M Luisa Roberts

Leonardus Wendelinus Mathias Marie Terstappen

Maria Luisa Paccagnella

Mrs Luisa Maria Paccagnella Paccagnella

Carrie Lynn Melvin

David Allen Chianese

Luisa Maria Paccagnella

Leonardus Wendelinus Terstappen

The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma ('PTCL'), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.

Methods of treating cancer with farnesyltransferase inhibitors

The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer in a subject having clinical signs of bone marrow homing of myeloid cells, including neutropenia, isolated neutropenia, a low percentage of peripheral blood blasts with or without a high percentage of bone marrow blasts, and/or a low ratio of peripheral blood blasts to bone marrow blasts, with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on hematological characteristics indicating bone marrow homing of myeloid cells.

The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.

Methods of treating cancer patients with farnesyltransferase inhibitors

The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on HRAS mutation status in the subject.

Enolase levels are predictive of the probability that a cancer patient will respond favorably to cancer therapy involving administration of hypoxia-activated achiral phosphoramide mustards.

Predictive biomarker for hypoxia-activated prodrug therapy

Growing community of inventors

Acton, MA, United States of America

Antonio Gualberto